Autism Spectrum Disorder

โ† Back to Index (๐Ÿ“ˆ Development and Growth)

Introduction and Epidemiology

Etiopathogenesis and Risk Factors

Risk Factor Category Specific Examples and Associations
Genetic Syndromes Fragile X syndrome, Tuberous sclerosis, Angelman syndrome, Rett syndrome, Smith-Lemli-Opitz syndrome, Timothy syndrome, Joubert syndrome.
Metabolic Disorders Phenylketonuria (untreated), congenital hypothyroidism, mitochondrial disorders.
Environmental / Parental Advanced maternal or paternal age, maternal obesity, short interpregnancy interval, premature birth.
Prenatal Exposures Intrauterine exposure to infections (e.g., rubella, cytomegalovirus).

Clinical Features (DSM-5 Diagnostic Criteria)

Deficits in Social Communication and Social Interaction

Restricted, Repetitive Patterns of Behavior, Interests, or Activities

DSM-5 Severity Levels

Severity Level Social Communication Impairment Restricted, Repetitive Behaviors
Level 3: Requiring very substantial support Severe deficits; very limited initiation of social interactions and minimal response to social overtures. Inflexibility of behavior markedly interferes with functioning in all spheres; great distress changing focus.
Level 2: Requiring substantial support Marked deficits apparent even with supports in place; limited initiation and abnormal responses to overtures. Inflexibility appears frequently enough to be obvious to casual observers; interferes with functioning.
Level 1: Requiring support Noticeable impairments without supports; difficulty initiating social interactions; atypical responses. Inflexibility causes significant interference with functioning in one or more contexts; problems with planning.

Co-occurring Conditions and Comorbidities

Domain Associated Conditions and Clinical Significance
Intellectual and Language Intellectual disability is present in 30โ€“50% of individuals. Approximately 40% of individuals with ASD remain non-verbal.
Behavioral Health ADHD is the most common comorbidity (40โ€“70%). Anxiety disorders (social and generalized) affect ~40%. Oppositional defiant disorder (16-28%) and depression (12-70%, mainly in older/high-functioning individuals) also frequently co-occur.
Neurologic Epilepsy occurs in 35-46% of individuals, with two incidence peaks: early childhood and adolescence. Catatonia (autism shutdown disorder) may emerge in adolescence.
Gastrointestinal & Nutrition GI problems (cyclic vomiting, constipation, gastroesophageal reflux disease) affect up to 70%. Avoidant and restrictive food intake disorder (ARFID) occurs in ~21%. Pica is seen in up to 25% of preschool-aged children.
Sleep Sleep problems, including delayed sleep onset and frequent night waking, affect 50โ€“80%. Abnormal baseline melatonin secretion may contribute.
Safety Wandering/elopement occurs in nearly 50% of children aged 4-10 years, carrying a high risk for near-drowning and traffic-related injuries. Increased risk for self-injury and aggression, particularly in those with limited language.

Differential Diagnosis

Screening Tests for Autism Spectrum Disorder (ASD)

Indications and Timing for Screening

Specific Autism Screening Tools

Screening Test Target Age Range Number of Items Clinical Details
Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT-R/F) 16โ€“48 months 20 items Takes 5โ€“10 minutes to administer; completed by parents; widely considered the best tool and best predictor for the development of ASD.
Parent's Observation of Social Interaction (POSI) Toddlers 7 items A brief, autism-specific screening tool completed by parents.
Survey of Well-Being of Young Children (SWYC) 16โ€“35 months (autism module) <5 items A comprehensive survey that includes an abbreviated screening instrument specifically for autism spectrum disorders.
Screening Tool for Autism in Toddlers and Young Children (STAT) 24โ€“35 months 12 items (average) Requires 20โ€“30 minutes to administer; evaluates key social and communicative behaviors.
Social Communication Questionnaire (SCQ) 4+ years 40 items (average) Takes 5โ€“10 minutes; utilized for older children to assess communication and social functioning.

Details of the M-CHAT-R/F

Broad-Band Screening and Surveillance

Diagnostic Approach and Evaluation

Genetic and Neurologic Investigations

Investigation Indications and Diagnostic Yield
Chromosomal Microarray (CMA) Considered first-tier etiologic testing. Positive in 10โ€“15% of all ASD individuals, and up to 30% in those with complex presentations (e.g., dysmorphisms, congenital anomalies).
Fragile X (FMR1) Testing Recommended for all males with ASD, and for females with suggestive physical features or a family history of X-linked ID, tremor/ataxia, or premature ovarian failure.
MECP2 Testing Recommended for females with ASD, and for males presenting with hypotonia, drooling, and frequent respiratory infections.
PTEN Gene Testing Indicated for all individuals with ASD and a head circumference greater than 2.5 standard deviations above the mean.
Neuroimaging (MRI) Indicated only for significant developmental regression, seizures, microcephaly, or focal neurologic findings. Not routinely indicated for macrocephaly alone.
Electroencephalogram (EEG) Indicated when there is clinical suspicion of seizures, spells, or significant developmental regression.
Whole Exome Sequencing (WES) Considered if initial genetic testing is negative; identifies single-nucleotide variants and provides a molecular diagnosis in nearly 30% of neurodevelopmental disorders.

Management

Developmental and Educational Interventions

Pharmacological Interventions

Medication Class Target Symptoms Common Side Effects and Monitoring
Atypical Antipsychotics (Risperidone, Aripiprazole) FDA-approved for severe irritability, aggression, and self-injurious behavior. Weight gain, metabolic syndrome, extrapyramidal movements, tardive dyskinesia. Requires laboratory monitoring (lipids, glucose, LFTs).
Stimulants (Methylphenidate, Amphetamines) Hyperactivity, impulsivity, and inattention (comorbid ADHD). Irritability, emotional lability, reduced appetite, insomnia, exacerbation of stereotypy. Monitor height, weight, BP, HR.
Alpha-2 Agonists (Clonidine, Guanfacine) Hyperactivity, impulsivity, inattention, and sleep-onset difficulties. Drowsiness, irritability, hypotension, dry mouth. Monitor BP and HR.
SSRIs (Sertraline, Fluoxetine) Anxiety, obsessive-compulsive behaviors, and depression. Behavioral activation, irritability, agitation, sleep disruption.
Melatonin Sleep-onset insomnia. Daytime sleepiness, enuresis, headache.

Complementary and Alternative Medicine (CAM)